The global Cytomegalovirus (CMV) treatment market is projected to grow from USD 627.36 million in 2024 to USD 1,035.16 million by 2032, expanding at a CAGR of 6.5% during the forecast period. CMV, a member of the herpesvirus family, affects people of all ages and is especially dangerous in immunocompromised individuals such as transplant recipients, HIV...